Innovating Works

.

Desconocido
Showing 1 to 20 of 74 results
EpiMetaPDO: Dissecting mechanisms of epigenetic reprogramming driving metastatic transition using cancer patient... IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Cancer development is a convoluted biological process that reshapes cellular identity. Genetic mutations are crucial in driving such process...
2024-04-17 - 2027-05-31 | Financiado
METABALANCANCER: Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: ERC-2023-STG The goal of this proposal is to explore combinations of targeted metabolite supplementation and global nutrient restriction as a new strateg...
2023-11-17 - 2028-11-30 | Financiado
FolLyway2HIT: Deciphering the role of immunoglobulin classes in shaping Follicular Lymphoma molecular heterogeneit... IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Follicular lymphoma (FL) is the second most common B cell neoplasm, characterized by the t(14;18) chromosomal translocation, resulting in de...
2023-07-13 - 2025-08-31 | Financiado
TELOVACCINE: Targeting telomeric DNA damage response as a new strategy to fight immunosenescence and improve vacc... IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: ERC-2022-POC2 The immune system is remodeled with age, going through a series of changes known as immunosenescence’, including the involution of primary l...
2023-06-06 - 2025-02-28 | Financiado
Sagittarius: A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE S... IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC). Approximately half of...
2023-04-27 - 2028-06-30 | Financiado
SHAPINCELLFATE: Impact of cell shapes on cell behaviour and fate IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS participó en un HORIZON EUROPE: ERC-2022-SYG Cells are often depicted as irregular spherical objects - the shape they adopt in suspension. However, the packed environment of tissues alt...
2023-03-06 - 2029-03-31 | Financiado
TARGET: Targeting DNA repair pathways sparking anti cancer immunity IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS participó en un H2020: ERC-2020-ADG This project will test for the first time the hypothesis that therapeutic inactivation of DNA repair pathways in cancer cells can be exploit...
2021-07-05 - 2026-09-30 | Financiado
PERSIST-SEQ: Building a reproducible single cell experimental workflow to capture tumour cell persistence IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by deve...
2021-06-28 - 2026-06-30 | Financiado
METAREPAIR: INVESTIGATING THE IMPACT OF NUTRITIONAL METABOLISM ON DNA DAMAGE REPAIR IN CANCER IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un H2020: H2020-MSCA-IF-2020 Preclinical and epidemiological studies indicate that some dietary patterns, such as high-fat diet (HFD), are associated with increased risk...
2021-04-21 - 2023-06-30 | Financiado
OrganVision: OrganVision Technology for real time visualizing and modelling of fundamental process in living org... OrganVision is a revolutionary technology proposition that will break new grounds in microscopy and develop an ideal imaging solution for or...
2021-01-27 - 2025-06-30 | Financiado
FIREQUENCHER: Pharmacological inhibition of macrophage activation IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un H2020: ERC-2019-PoC Macrophages are innate immune cells that specialise in sensing and responding to the presence of pathogens and they have been causally invol...
2020-10-07 - 2022-06-30 | Financiado
BCRlossToBWinner: Genetic determinants promoting resistance to BCR loss in B cell lymphomas IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un H2020: H2020-MSCA-IF-2019 Loss of B-Cell Receptor (BCR) in lymphoma B cells leads to attenuated PI3K/AKT signaling and altered Myc-dependent transcriptional output, r...
2020-03-26 - 2023-11-25 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.